New York, NY -- November 23, 2021 -- InvestorsHub
NewsWire -- Tauriga Sciences, Inc. (OTCQB:
TAUG) (“Tauriga” or the “Company”), a New York based
diversified Life Sciences Company, today announced the results of
its Special Meeting of stockholders held at 9:00am EST on November
22, 2021.
At the Special Meeting, Tauriga’s stockholders approved an
amendment to our Articles of Incorporation (collectively, “Proposal
1”) to: (i) allow for consideration of the change of the name of
our Company to Sublingual Technologies Inc.; (ii) allow action by
our Board of Directors to affect a change in the name of our
Company without further shareholder approval; and (iii) to increase
the total number of authorized shares of common stock, par value
$.00001 per share (“Common Stock”) from 400,000,000 to 750,000,000
shares.
In addition, following the appointment of James V. Rosati and
Chris Sferruzzo in March 2021 to the Company’s Board of Directors,
in Proposal 2 of the Proxy Statement, we nominated the following
slate of persons for election to the Company’s Board of Directors:
Seth M. Shaw, Thomas J. Graham, James V. Rosati and Chris
Sferruzzo. All of the foregoing nominees were overwhelmingly
elected by our stockholders to serve as members of our Board of
Directors.
Seth M. Shaw, Chief Executive Officer of Tauriga Sciences,
stated, “The passage of all the matters put before the stockholders
in this Special Meeting represent important milestones for the
Company. We are grateful for the support shown by our stockholders
and we thank everyone for his/her vote of confidence. I have spoken
with many of you this last week and I appreciate your time, input,
concerns, and advice. The Company is confident that it now has the
flexibility and wherewithal to move ahead with important corporate
initiatives – including its ongoing pharmaceutical development
efforts. The Company is laser focused on creating
shareholder value in the short, intermediate, and long terms.”
ABOUT TAURIGA SCIENCES INC.
Tauriga Sciences, Inc. (TAUG)
is a revenue generating, diversified life sciences company, engaged
in several major business activities and initiatives. The company
manufactures and distributes several proprietary retail products
and product lines, mainly focused on the Cannabidiol (“CBD”) and
Cannabigerol (“CBG”) Edibles market segment. The main product line,
branded as Tauri-Gum™, consists of a proprietary supplement chewing
gum that is Kosher certified, Halal certified, and Vegan Formulated
(CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate),
(CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant),
(Vitamin C + Zinc Infused Tauri-Gum™ Flavor: Pear Bellini),
(Caffeine Infused Tauri-Gum™ Flavor: Cherry Lime Rickey), &
(Vitamin D3 Infused Tauri-Gum™ Flavor: Golden Raspberry). The
Company’s commercialization strategy consists of a broad array of
retail customers, distributors, and a fast-growing E-Commerce
business segment (E-Commerce website: www.taurigum.com). Please visit our
corporate website, for additional information, as well as
inquiries, at http://www.tauriga.com Complementary
to the Company’s retail business, is its ongoing Pharmaceutical
Development initiative. This relates to the development of a
proposed Pharmaceutical grade version of Tauri-Gum™, for nausea
regulation (specifically designed for the following indication:
Patients Subjected to Ongoing Chemotherapy Treatment). On March 22,
2021, the Company announced that it had Converted its U.S.
Provisional Patent Application (filed on March 17, 2020) into a
U.S. Non-Provisional Patent Application. The Patent, filed with the
U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF
MANUFACTURING, AND METHODS OF TREATMENT”. On December 18, 2020 the
Company disclosed that it had entered into a Master Services
Agreement with CSTI to lead the Company’s clinical development
efforts.
The Company is headquartered in Wappingers Falls, New York. In
addition, the Company operates two full time E-Commerce fulfillment
centers: one located in Montgomery, Texas and the other in
Brooklyn, New York.
DISCLAIMER — Forward-Looking Statements
This press release contains certain “forward-looking statements”
as defined by the Private Securities Litigation Reform Act of 1995
which represent management’s beliefs and assumptions concerning
future events. These forward-looking statements are often indicated
by using words such as “may,” “will,” “expects,” “anticipates,”
believes, “hopes,” “believes,” or plans, and may include statements
regarding corporate objectives as well as the attainment of certain
corporate goals and milestones. Forward-looking statements are
based on present circumstances and on management’s present beliefs
with respect to events that have not occurred, that may not occur,
or that may occur with different consequences or timing than those
now assumed or anticipated. Actual results may differ materially
from those expressed in forward looking statements due to known and
unknown risks and uncertainties, such as are not guarantees of
general economic and business conditions, the ability to
successfully develop and market products, consumer and business
consumption habits, the ability to consummate successful
acquisition and licensing transactions, fluctuations in exchange
rates, and other factors over which Tauriga has little or no
control. Many of these risks and uncertainties are discussed in
greater detail in the “Risk Factors” section of Tauriga’s Form 10-K
and other periodic filings made from time to time with the
Securities and Exchange Commission. Such forward-looking statements
are made only as of the date of this release, and Tauriga assumes
no obligation to update forward-looking statements to reflect
subsequent events or circumstances. You should not place undue
reliance on these forward-looking statements.
Contact:
Tauriga Sciences, Inc.
4 Nancy Court, Suite 4
Wappingers Falls, NY 12590
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
Company Instagram: @taurigum
Personal Instagram: @sethsms47
Twitter: @SethMShaw
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Apr 2024 to May 2024
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From May 2023 to May 2024